Riyadh biotech summit closes with SAR 5.5 billion in deals
- Summit closed with more than SAR 5 billion (USD 1.33 billion) in agreements
- Deal value up sharply from more than USD 100 million in 2024
- Vaccine Industrial Company's SAR 500 million facility is 85 percent complete
- KAIMRC and Thermo Fisher announced a genomics Center of Excellence
- Over 15,000 visitors from 57 countries attended the four-day event
*this image is generated using AI for illustrative purposes only.
The Riyadh Global Medical Biotechnology Summit concluded its fourth edition on September 17, 2026, with more than SAR 5 billion (USD 1.33 billion) in agreements, signaling accelerated investment in the Kingdom's life sciences sector.
The event saw participation from more than 15,000 visitors across 57 countries and 120 sponsors. The deal value represents a substantial increase from the more than USD 100 million generated at the 2024 edition.
Key Agreements and Investments
The summit facilitated over 40 agreements across four strategic pillars: government strategy, investment, research readiness, and capability building.
| Partner | Deal/Initiative | Value/Scale |
|---|---|---|
| Vaccine Industrial Company | Human vaccine facility | SAR 500 million investment |
| Sanabil Studio & Telepath | AI and digital pathology | USD 3 million potential investment |
| Life Sciences Innovation Forum | Investment fund engagement | More than USD 120 million |
| KAIMRC & Thermo Fisher | Genomics Center of Excellence | Research collaboration |
Vaccine Industrial Company confirmed that its SAR 500 million human vaccine manufacturing facility is 85 percent complete. The project spans 42,000 square meters and plans to localize up to 80 percent of the Kingdom's essential vaccine needs.
In the digital health space, Sanabil Studio by Redesign Health signed with Telepath by Tahlili for an AI and digital pathology partnership with a potential investment of USD 3 million.
Research and Talent Development
King Abdullah International Medical Research Center (KAIMRC) announced a Center of Excellence for Genomics, Proteomics, and Biobanking with Thermo Fisher Scientific. Additional research collaborations were signed with Olink, Tiziana Life Sciences, and Japan's Chiyoda Corporation.
The University Hospitals Program signed with Novo Nordisk to build clinical trial capability. King Saud University partnered with BioMe of South Korea for a microbiome joint venture, while Najran University launched the Najran Genomic Biobank Initiative.
Talent development initiatives included a partnership between KAIMRC and Rutgers University for AI research and training. Princess Nourah bint Abdulrahman University and Cellenkos launched a program for Saudi female talent in cell and gene therapy.
What the Numbers Show
The deal value at RGMBS 2026 (USD 1.33 billion) is more than 13 times higher than the USD 100 million recorded in 2024. This sharp increase suggests a shift from early-stage networking to large-scale capital deployment and infrastructure completion, evidenced by the SAR 500 million vaccine plant nearing final stages.
How will the completion of the Vaccine Industrial Company's facility impact Saudi Arabia's reliance on imported vaccines and global supply chain dynamics in the region?
What regulatory hurdles might the AI and digital pathology partnership between Sanabil Studio and Telepath face before achieving widespread clinical adoption?
To what extent will the new talent development programs, particularly for female scientists in cell and gene therapy, help retain local expertise and reduce brain drain?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
